Unigene Laboratories

Unigene secures financing to extend operations, cuts 40% of staff

Tuesday, April 9, 2013 08:00 AM

Unigene Laboratories, a biopharmaceutical company focused on peptide-based therapeutics, has entered into a second amendment to a financing agreement with affiliates of Victory Park Capital Advisors (VPC), whereby VPC has agreed to purchase an additional $750,000 senior secured note, providing Unigene with additional working capital.

More... »

Unigene appoints Mayes and Pepper to biotechnologies SBU

Friday, February 10, 2012 11:48 AM

Unigene Laboratories announced the expansion of its biotechnologies strategic business unit (SBU) with the promotion of Gregory T. Mayes to chief business officer and appointment of Jane Pepper to senior director, business development.

More... »

Tarsa to advance clinical programs with $24.5M financing

Wednesday, July 13, 2011 10:02 AM

Tarsa Therapeutics reported progress in its two ongoing clinical development programs for its oral recombinant salmon calcitonin for the treatment and prevention of postmenopausal osteoporosis. Patient enrollment in the phase II osteoporosis prevention trial has been completed, and the full set of data from the phase III ORACAL trial has been accepted for an oral presentation at the American Society for Bone and Mineral Research (ASBMR) 2011 annual meeting in September. Separately, Tarsa also said it has closed an additional financing round that raised a total of $24.5 million.

More... »

Unigene accelerates anorexigenic peptide

Monday, March 7, 2011 07:36 AM

Unigene Laboratories said its lead proprietary anorexigenic peptide, UGP281, is progressing. An anorexigenic peptide diminishes or controls appetite and offers potential therapeutic benefit to morbidly obese patients. The company will file an Investigational New Drug (IND) application with the FDA and initiate phase I clinical studies in 2012.

More... »